Poseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at ASH

Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data from the company’s B-cell maturation antigen (BCMA) specific chimeric antigen receptor (CAR) T-cell drug candidate, referred to as P-BCMA-101. Data demonstrated a superior stem cell memory phenotype and self-renewal capacity, as well as strong and persistent anti-tumor activity in an established xenograft model of multiple myeloma. The company plans to initiate a Phase 1 clinical trial of P-BCMA-101 for the treatment of patients with relapsed or refractory multiple myeloma in 2017. These data were featured across three presentations at the American Society of Hematology (ASH) Annual Meeting taking place December 3-6, 2016.